Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Little Green Pharma Ltd. ( (AU:LGP) ) has provided an announcement.
Little Green Pharma has reported a change in the holdings of director Michael David Lynch-Bell following the exercise of vested retention share rights. On 26 February 2026, Lynch-Bell converted 140,000 retention share rights into ordinary shares at no cash consideration, increasing his direct holding from 1,828,450 to 1,968,450 ordinary shares while eliminating that specific tranche of rights.
Following this transaction, Lynch-Bell now holds 1,968,450 ordinary shares and retains 300,000 retention share rights vesting in March 2027. The exercise of retention rights signals ongoing alignment of the director’s interests with shareholders and reflects the company’s use of equity-based incentives to retain and reward key management without immediate cash outlay.
The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd is an Australian-listed company in the healthcare and pharmaceuticals sector. It is focused on the development and commercialisation of medicinal cannabis products, targeting regulated medical markets and patients seeking cannabis-based therapies.
Average Trading Volume: 218,318
Technical Sentiment Signal: Sell
Current Market Cap: A$35.15M
For an in-depth examination of LGP stock, go to TipRanks’ Overview page.